Clinical trial · Interventional
Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium
Modulation of Death Effector Expression By Short-Term Exposure to Low-Dose Interferon
NCT00082719CI-TRIAL-00017918completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of urothelial cancer. PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in treating patients with cancer of the urothelium.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Urethral Cancer | Malignant Urethral Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Recombinant Interferon Alfa | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Low-dose interferon alfa subcutaneously (SC) twice daily.
- interventionNames
- Biological: Recombinant Interferon Alfa
- type
- EXPERIMENTAL
- label
- Arm II
- description
- Interferon alfa as in arm I at a higher dose.
- interventionNames
- Biological: Recombinant Interferon Alfa
- type
- EXPERIMENTAL
- label
- Arm III
- description
- Interferon alfa SC once daily.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients must have histologically proven urothelial cancer, known or suspected (e.g. by outside evaluation) to be muscle-invasive, and be scheduled for cystoscopy and transurethral biopsy as part of their routine evaluation at M. D. Anderson. 2. Patients must understand the investigational nature of this study and provide written, informed consent. Exclusion Criteria: 1. Patients who are pregnant or lactating are not eligible. Women of child-bearing potential must have a negative pregnancy test before starting therapy. 2. Patients with current symptoms suggestive of clinically significant affective disorder. 3. Patients taking more than physiologic replacement doses of corticosteroids are not eligible.
References
Publications (0)
Data not yet available
No reference posted for this study.